Riva Therapeutics is a precision oncology company focused on creating transformative medicines for cancer patients. We are developing a new generation of small molecule therapeutics by leveraging deep knowledge of genomic dependencies to selectively target essential tumor cell processes beyond DNA damage repair.  Our precision lethal therapies have the potential to provide profound clinical activity, be well-tolerated, and substantially improve patient lives.​

We are on course to rapidly discover a new generation of small molecule oncology medicines – “precision lethal” therapies that are highly effective and well-tolerated for large patient populations.